Irinotecan (except for liposomal formulations): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001783/202005
(PDF/108.72 KB)
for the implementation - PSUSA/00001783/202005 … for the implementation - PSUSA/00001783/202005 Other languages: bg cs da … interval covered by this PSUSA procedure, signals of drug-drug …
Last updated: 15/03/2021
Active substance: irinotecan
Procedure number: PSUSA/00001783/202005
Regulatory outcome: Variation
